Epstein-Barr virus causes a ubiquitous infection in adults worldwide. It is also a oncogenic virus that is associated with many cancers, including nasopharyngeal carcinoma which is one of the predominant tumor in South China. However, so far, a vaccine against Epstein-Barr virus was not yet available in the world and there is no effective immunotherapy against those Epstein-Barr virus associated carcinomas. With the advantages of high stability, biocompatibility, low toxicity and multifunctional regions, the nextgeneration nanoparticles has been successfully applied in the research of Epstein-Barr virus vaccines. In this article, the recent advances of nanoparticles, including exosomes, virus-like particles, self-assembling ferritin nanoparticles and other nanoparticles using for prevention and against of Epstein-Barr virus infections have been reviewed and further discussed. Finally, the opportunities and challenges faced by engineered nanoparticles in the clinical application are prospected.